HALCON Unveils UAE’s First Air Defence Missile
23.2.2021 19:40:00 EET | Business Wire | Press release
HALCON, a regional leader in the production and supply of precision-guided weapons, today unveiled SkyKnight - the first UAE designed and manufactured counter-rocket, artillery, and mortar (C-RAM) missile system, at the International Defence and Exhibition Conference (IDEX) 2021.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210223005887/en/
SkyKnight - the first UAE designed and manufactured counter-rocket, artillery, and mortar (C-RAM) missile system - (Photo: AETOSWire)
EDGE, the parent company of HALCON, has been developing a short-range air defence system, as has Germany-based Rheinmetall AG, which was actively seeking a missile system to form part of its Skynex air defence system. The companies decided to jointly offer a solution, with HALCON providing SkyKnight, the missile system to the highly regarded Oerlikon Skynex Air Defence System, which sets new standards with its unique open architecture.
HALCON’s SkyKnight was purposely designed to counter the full spectrum of modern threats, providing early warning signals and precise surface-to-air intercept capabilities targeting of rotary-wing aircraft, unmanned aerial vehicles (UAVs) rockets, artillery, mortar, and other fixed-wing aircraft at a range of up to 10Km.
Commenting on this landmark international elevation of a UAE-manufactured missile, H.E. Faisal Al Bannai, EDGE Group CEO and Managing Director said: “SkyKnight is the UAE’s first, but will not be the last air defence missile developed by HALCON. We are pleased to team up with Rheinmetall, a leading player in the defence industry, for us to jointly offer the world’s most advanced and comprehensive C-RAM solution leveraging our SkyKnight missile and Rheinmetall’s Skynex solution. This collaboration is a clear message that EDGE is open to teaming up with various players to offer joint advance solutions.”
The Oerlikon Skynex air defence system comprises the Oerlikon Skynex control node, multi-sensor units (MSU) featuring active electronically scanned multi-mode radars (AMMR), multiple 35mm revolver guns RG Mk3 and HALCON’s SkyKnight C-RAM missiles and missile launchers, each of which has a capacity of 60 missiles. HALCON’s C-RAM missile is capable of tracking and neutralising numerous, multi-directional incoming targets at one time, providing protection for static assets, as well as for mobile and mechanised forces. Transportable and mobile, the system can be deployed fixed on land, sea and moving land platform.
Rheinmetall AG, through its Swiss subsidiary, Rheinmetall Air Defence, has deployed the Skyguard system in numerous countries, which can bring down fast, small targets, and is used as the inner tier of layered air defence of vital points and critical military infrastructure. Countries that have rolled out Skyguard systems will ultimately upgrade to Skynex, placing HALCON, its SkyKnight C-RAM missile system, and the UAE at the forefront of air defence system innovation.
HALCON is part of the Missiles & Weapons cluster within EDGE, an advanced technology group for defence that ranks among the top 25 military suppliers in the world.
About EDGE
EDGE is an advanced technology group established to develop agile, bold and disruptive solutions for defence and beyond. Enabling a secure future, it is dedicated to bringing innovative technologies and services to market with greater speed and efficiency. Consolidating over 25 entities and employing more than 13,000 brilliant minds, it offers expertise across five core clusters: Platforms & Systems, Missiles & Weapons, Cyber Defence, Electronic Warfare & Intelligence and Mission Support. Headquartered in Abu Dhabi, United Arab Emirates, EDGE is a catalyst for change – set to revolutionise the industry and change its fundamentals.
For more information, visit edgegroup.ae
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210223005887/en/
Contact information
EDGE Group Press Office
Thushara Mohanan,
media@edgegroup.ae
+971555080413
+971553584520
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AI Meets Traditional Culture: Huangshan Captures Widespread Attention at ITB Berlin7.3.2026 11:22:00 EET | Press release
Huangshan, one of China’s most iconic scenic destinations, drew significant attention at this year’s ITB by presenting a compelling fusion of traditional Chinese culture and cutting-edge artificial intelligence under the slogan “The world of Huangshan is for the world.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260307909978/en/ International visitor admires Huangshan cultural and creative exhibits at the Huangshan stand during ITB Berlin. Located in eastern China’s Anhui Province, Huangshan is famed for its “Five Natural Wonders” — fantastic pines, grotesque rocks, sea of clouds, hot spring and winter snow. The mountain is widely regarded as one of China’s greatest mountain landscapes. It is also a rare natural heritage site that simultaneously holds multiple international designations, including UNESCO World Cultural and Natural Heritage status, a UNESCO Global Geopark and a World Biosphere Reserve. At ITB, the Huangsh
Incyte Announces the European Commission Approval of Zynyz ® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 23:42:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meury, President and Chief Executive Officer, Incyte. “As the first PD-1 immunotherapy approved in Europe in combination with platinum-based chemotherapy in the first-line setting, Zynyz helps expand the standard-of-care options available to clinicians and underscores our commitment to delivering innovative medicines that can have an impact for patients.” The EC decision follows the January 2026 positive opinion received from the European Medicines Agency’s Committee f
Dfns Launches Payouts6.3.2026 22:27:00 EET | Press release
Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i
Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 21:23:00 EET | Press release
Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up
Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG6.3.2026 19:30:00 EET | Press release
Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business. Headquartered in Basel, Switzerland, CHI operates globally across the Americas, Europe and Asia Pacific. The business comprises three segments: Hard Empty Capsules: leading global manufacturer of gelatin and plant-based capsules offering a broad range of innovative solutions for pharmaceutical and nutraceutical customers. Dosage Form Solutions: end-to-end development and manufacturing platform serving nutraceutical and pharmaceutical customers. Health Ingredients: provider of branded, science-backed nutrition ingredients serving joint health, energy and active lifestyle markets. Lone Star believes CHI is a high-quality, globally recognized platform with strong technical capabilities, different
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom